论文部分内容阅读
[目的]观察艾司西酞普兰联合舍曲林治疗肠易激综合征(IBS)患者的临床疗效和安全性。[方法]使用随机数字表法将59例在我院治疗的IBS者分为对照组27例和治疗组32例,对照组患者口服舍曲林10mg,2次/d治疗,治疗组在对照组治疗基础上加用艾司西酞普兰10mg,1次/d;3个月为1个疗程,疗程结束后比较临床疗效和单项症状(腹痛、腹泻、黏液便)总有效率,治疗前后使用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)进行评分,记录不良反应。[结果]治疗组总有效率为93.8%,高于对照组的77.8%(P<0.05);对照组的腹痛和腹泻改善总有效率分别为70.4%和59.3%,治疗组为84.4%和90.6%,明显好于对照组(P<0.05);治疗组黏液便改善情况好于对照组,但差异无统计学意义(P>0.05);2组治疗后HAMD、HAMA评分均较治疗前下降(P<0.05),且治疗组明显低于对照组(P<0.05)。2组不良反应包括失眠、食欲不振和恶心,停药后即好转。[结论]艾司西酞普兰联合舍曲林治疗IBS患者疗效显著,可显著改善患者的焦虑和抑郁情绪,安全性较好,值得临床推广应用。
[Objective] To observe the clinical efficacy and safety of escitalopram plus sertraline in the treatment of patients with irritable bowel syndrome (IBS). [Method] Fifty-nine IBS patients treated in our hospital were divided into control group (n = 27) and treatment group (n = 32) by random number table method. Patients in the control group were treated with sertraline 10 mg twice daily, Treatment with escitalopram 10mg, 1 / d; 3 months for a course of treatment, after the end of the course of clinical efficacy and individual symptoms (abdominal pain, diarrhea, mucus will be) the total effective rate before and after treatment using Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA) were scored and adverse reactions recorded. [Results] The total effective rate in the treatment group was 93.8%, which was higher than that in the control group (77.8%, P <0.05). The total effective rate in the control group was 70.4% and 59.3%, respectively, 84.4% and 90.6% in the treatment group %, Which were significantly better than those in the control group (P <0.05). The improvement of mucus in the treatment group was better than that in the control group, but the difference was not statistically significant (P> 0.05). The HAMD and HAMA scores of the two groups were decreased P <0.05), and the treatment group was significantly lower than the control group (P <0.05). Adverse reactions in 2 groups included insomnia, loss of appetite and nausea, which improved after stopping treatment. [Conclusion] Escitalopram in combination with sertraline has significant curative effect in patients with IBS, which can significantly improve the patients’ anxiety and depression, which is safe and worthy of clinical application.